Abstract
Estimating an epidemic’s trajectory is crucial for developing public health responses to infectious diseases, but incidence data used for such estimation are confounded by variable testing practices. We show instead that the population distribution of viral loads observed under random or symptom-based surveillance, in the form of cycle threshold (Ct) values, changes during an epidemic and that Ct values from even limited numbers of random samples can provide improved estimates of an epidemic’s trajectory. Combining multiple such samples and the fraction positive improves the precision and robustness of such estimation. We apply our methods to Ct values from surveillance conducted during the SARS-CoV-2 pandemic in a variety of settings and demonstrate new approaches for real-time estimates of epidemic trajectories for outbreak management and response.
Competing Interest Statement
ML discloses honoraria/consulting from Merck, Affinivax, Sanofi-Pasteur, and Antigen Discovery; research funding (institutional) from Pfizer, and unpaid scientific advice to Janssen, Astra-Zeneca, and Covaxx (United Biomedical). MJM is a medical advisor for Detect.
Funding Statement
This work is supported by U.S. National Institutes of Health Director’s Early Independence Award DP5-OD028145 (MJM, JAH), the Morris-Singer Fund (LKS and ML), U.S. Centers for Disease Control and Prevention Award U01IP001121 (LKS and ML), and U.S. National Institute of General Medical Sciences award U54GM088558 (ML, JAH, LKS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was obtained from Harvard School of Public Health for use of de-identified hospital-based viral load data (IRB 20-1703) and the Broad institute ORSP provided an exempt approval states for use of surveillance-based Ct values.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Significant additions to the methodology, figures and analyses.
Data Availability
All code to perform the analyses and generate the figures presented in this article is available at https://github.com/jameshay218/virosolver_paper and https://github.com/jameshay218/virosolver. Simulated data and real data used in the analyses are also available at https://github.com/jameshay218/virosolver_paper. For the model fitting, code for the Markov chain Monte Carlo framework is available at https://github.com/jameshay218/lazymcmc and https://github.com/jameshay218/lazymcmc/tree/parallel_tempering. The authors used code developed by Abbott et al. to estimate Rt from reported case counts; this is available at https://github.com/epiforecasts/EpiNow2.
